Market Cap
$2.1B
BCRX
BIOCRYST PHARMACEUTICALS INC
$8.07 ▼ -0.55%
Prev close $8.12Market cap$2.1B
ConsensusStrong Buy
12-mo target$20.73 (+156.7%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)35 New Institutional Positions15 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on BCRX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$1.8B
Inst. Activity
35 buys / 15 sells
Insider Activity
$0.00 buy / $2.6M sell
Insider Net $
-$2.6M
Social Sentiment
50° Neutral
SEC Reports
11
Press Releases
1
Congressional
1 trades
Price chart 30d -20.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: BCRX — 69.8% short (1.5M / 2.1M)
Short: 1,458,531 | Exempt: 4,408 | TRF Vol: 2,088,729 | Short Ratio: 69.8% | Off-exchange volume (da
Aug 31, 2026 Insider
McKee Amy E was granted 644 shares
Director @ $9.70 ($6.2K)
Aug 31, 2026 Insider
Milne Jill C. was granted 1,288 shares
Director @ $9.70 ($12.5K)
Aug 31, 2026 Insider
Aug 5, 2026 SEC Stonehouse Jon P was granted 644 shares
Director @ $9.70 ($6.2K)
BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue of $218.3M, beating
8-K — Impact 7/10
Jul 10, 2026 Congress
Jul 3, 2026 SEC Gilbert Cisneros buy
$1,001 - $15,000 — House
BioCryst is discontinuing its internal discovery programs and closing its Birmingham, Alabama research facility by year-
8-K — Impact 5/10
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
4,481,874 shares ($44.8M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Sep 10, 2026 | RBC Capital | DOWNGRADE | Sector Perform | 55% |
| Sep 8, 2026 | Needham | REITERATE | Buy | 50% |
| Aug 6, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 6, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Jul 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jun 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 30, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| May 7, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| May 7, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 10 | 2 | 0 | 0 | 88% | |
| Aug 1, 2026 | 5 | 10 | 2 | 0 | 0 | 88% | |
| Jul 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% |
Price targets
Where 11 covering analysts think BCRX trades over the next 12 months.
$20.73 +156.7% upside Strong Buy
Current$8.08 Low$11.00 Median$17.00 High$32.00 11 analysts
$11.00$32.00
Analyst rating Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 8 neutral · avg impact 4.5/10.Plus 1 press releases.
BULLISH8-K7/10
BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue
Aug 5, 2026
NEUTRAL8-K5/10
BioCryst is discontinuing its internal discovery programs and closing its Birmingham, Alabama resear
Jul 3, 2026
NEUTRAL8-K3/10
BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to
Jun 12, 2026
NEUTRALCLUSTER3/10
Two BioCryst insiders sold a total of $697K in open-market sales within a week of Q1 2026 earnings.
May 19, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
short_volume
Short Volume: BCRX — 69.8% short (1.5M / 2.1M)
Short: 1,458,531 | Exempt: 4,408 | TRF Vol: 2,088,729 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: BCRX — 59.6% short (1.4M / 2.3M)
Short: 1,368,846 | Exempt: 0 | TRF Vol: 2,297,904 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: BCRX — 70.7% short (1.4M / 2.0M)
Short: 1,425,950 | Exempt: 549 | TRF Vol: 2,015,534 | Short Ratio: 70.7% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: BCRX — 63.2% short (0.7M / 1.1M)
Short: 711,532 | Exempt: 5,229 | TRF Vol: 1,125,093 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: BCRX — 69.3% short (1.0M / 1.5M)
Short: 1,020,261 | Exempt: 62 | TRF Vol: 1,472,110 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.12 | $0.11–$0.12 | -28.1% | +9.5% | 2↑ 0↓ | $0.2B | 2 |
| Next Q | $0.13 | $0.10–$0.15 | -40.0% | +56.3% | 2↑ 0↓ | $0.2B | 2 |
| Current FY | $0.74 | $0.70–$0.79 | 17.4% | +12.9% | 1↑ 1↓ | $0.7B | 2 |
| Next FY | $0.94 | $0.73–$1.15 | 26.2% | -6.0% | 0↑ 2↓ | $0.7B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.115 | — |
| 7d ago | $0.125 | -0.010 |
| 30d ago | $0.105 | +0.010 |
| 60d ago | $0.105 | +0.010 |
| 90d ago | $0.105 | +0.010 |
Institutional ownership
Which big funds own BCRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.8B total value (176,969,655 shares) as of 2026-Q2. Top holders: BlackRock,, RA, STATE. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 23,893,036 | $238.9M | 13.5% | — |
| RA CAPITAL MANAGEMENT, L.P. | 15,827,186 | $158.3M | 8.9% | — |
| STATE STREET CORP | 15,191,098 | $151.9M | 8.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 11,364,236 | $113.6M | 6.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11,139,158 | $111.4M | 6.3% | — |
| Jupiter Topco LLC | 9,540,764 | $95.3M | 5.4% | — |
| TWO SIGMA INVESTMENTS, LP | 6,775,349 | $67.8M | 3.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 6,248,046 | $62.5M | 3.5% | — |
| Aberdeen Group plc | 5,310,871 | $53.1M | 3.0% | — |
| UBS Group AG | 5,078,280 | $50.8M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | 2,347,443 | 4,481,874 | +90.9% | $44.8M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 187,721 | 3,394,729 | +1708.4% | $33.9M |
| JANE STREET GROUP, LLC | DOUBLED | 622,607 | 2,762,683 | +343.7% | $27.6M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 776,990 | 2,530,290 | +225.7% | $25.3M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | ADD | 1,227,040 | 1,844,912 | +50.4% | $18.4M |
| CITADEL ADVISORS LLC | ADD | 1,018,743 | 1,759,160 | +72.7% | $17.6M |
| JUPITER ASSET MANAGEMENT LTD | ADD | 1,196,371 | 1,642,874 | +37.3% | $16.4M |
| IMC-Chicago, LLC | DOUBLED | 631,290 | 1,634,336 | +158.9% | $16.3M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 2,815,304 | 1,195,651 | -57.5% | $12.0M |
| Pictet Asset Management Holding SA | DOUBLED | 471,573 | 1,249,771 | +165.0% | $12.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 44 transactions. Net -$2.6M — $0.00 bought, $2.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | McKee Amy E | Director | AWARD | 644 | $9.70 | $6.2K |
| Aug 31, 2026 | Milne Jill C. | Director | AWARD | 1,288 | $9.70 | $12.5K |
| Aug 31, 2026 | Stonehouse Jon P | Director | AWARD | 644 | $9.70 | $6.2K |
| Aug 31, 2026 | Frank Steven | Director | AWARD | 1,288 | $9.70 | $12.5K |
| Aug 31, 2026 | MILANO VINCENT | Director | AWARD | 1,159 | $9.70 | $11.2K |
| Jun 11, 2026 | Frank Steven | Director | AWARD | 15,294 | — | — |
| Jun 11, 2026 | Frank Steven | Director | AWARD | 33,540 | — | — |
| Jun 11, 2026 | LEVIN ALAN G | Director | AWARD | 15,294 | — | — |
| Jun 11, 2026 | LEVIN ALAN G | Director | AWARD | 33,540 | — | — |
| Jun 11, 2026 | Galson Steven K | Director | AWARD | 15,294 | — | — |
Congressional trades
BCRX trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BioCryst Pharmaceuticals Inc | Sep 7, 2026(60d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BCRX.
Shares short
34,868,460
Settlement Sep 15, 2026
Change vs prior
+2.4%
Semi-monthly cycle
Days to cover
7.3
At avg daily volume
Of shares outstanding
≈13.7%
Estimate — not % of float
All BCRX filing & press-release reports (12)
- 8-K reportAug 5, 2026
- 8-K reportJul 3, 2026
- 8-K reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- CLUSTER reportMay 19, 2026
- 144 reportMay 13, 2026
- 8-K reportMay 6, 2026
- 8-K reportMay 4, 2026
- DEFA14A reportApr 23, 2026
- PRESS-RELEASE reportApr 15, 2026
- CLUSTER reportMar 24, 2026
- 8-K reportFeb 26, 2026